Potential role of transmembrane 9 superfamily member 1 as a biomarker in urothelial cancer

doi:10.5306/wjco.v15.i8.965

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (173)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

139

Sum=143

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=26

Aug 24, 2024 (publication date) through Aug 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Aug 24, 2024; 15(8): 965-967
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.965

Potential role of transmembrane 9 superfamily member 1 as a biomarker in urothelial cancer

Alvaro Pinto, Abrahams Ocanto, Felipe Couñago

Alvaro Pinto, Department of Medical Oncology, University Hospital La Paz, Paseo Castellana 261, Madrid 28046, Spain

Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare, Hospital Universitario San Francisco de Asís, Madrid 28002, Spain

Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare, Vithas La Milagrosa University Hospital, Madrid 28010, Spain

Felipe Couñago, National Director GenesisCare, Madrid 28043, Spain

Author contributions: Pinto A contributed to the discussion and design of the manuscript; Pinto A, Ocanto A and Couñago F designed the overall concept, outline of the manuscript, contributed to the writing, and editing the manuscript and review of the literature; All authors contributed to this paper.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Alvaro Pinto, PhD, Doctor, Department of Medical Oncology, University Hospital La Paz, Paseo Castellana 261, Madrid 28046, Spain. alvaropintomarin@gmail.com

Received: January 11, 2024
Revised: June 15, 2024
Accepted: July 4, 2024
Published online: August 24, 2024
Processing time: 218 Days and 1.2 Hours

Core Tip

Core Tip: The overexpression of transmembrane 9 superfamily member 1 promotes cells into the gap 2/mitosis phase of the cell cycle and has a role in autophagy and immune-mediated mechanisms, therefore, the potential inhibition of transmembrane 9 superfamily member 1 or related pathways could result in antitumoral activity, providing a new target in the treatment of patients with bladder cancer.